ea0025p176 | Endocrine tumours and neoplasia | SFEBES2011
, Owen Laura
, Keevil Brian
The measurement of plasma renin activity is required in a number of clinical situations, in particular screening for primary aldosteronism (PA) and monitoring mineralocorticoid replacement therapy. PA is a treatable cause of hypertension and has an estimated prevalence of up to 20% amongst resistant hypertensives. Consequently, recent guidelines now recommend screening for PA in all patients groups with a high prevalence of PA. At present, the most reliable method of screening...